Myeloma clinical trials at UCSF
1 research study open to eligible people
Myeloma is a type of blood cancer found in plasma cells. UCSF is testing new treatments for patients whose myeloma returned after previous therapies. One trial is studying the effects of a specific inhibitor on patients with resistant forms of myeloma.
MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
open to eligible people ages 18 years and up
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
San Francisco, California and other locations
Our lead scientists for Myeloma research studies include Alfred Chung.
Last updated: